Streetbeat News

Regulatory

MYGN

Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential securities law violations. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test from January 2025.

Portfolio Pulse from

November 17, 2024 | 4:00 pm

CRLBF

The US cannabis industry is showing resilience with a projected growth from $30 billion to over $50 billion by 2030. Recent stock pullbacks present investment opportunities, especially with federal legalization efforts gaining momentum. Investors are advised to use technical analysis for informed decisions.

Portfolio Pulse from

November 17, 2024 | 3:45 pm

O

Realty Income (NYSE:O) is expected to benefit from potential interest rate cuts, improved corporate tax rates, and economic growth during Trump's presidency, despite a 2% decline in its stock since his election.

Portfolio Pulse from

November 17, 2024 | 3:00 pm

SMH

The VanEck Semiconductor ETF (SMH) is rated as a Hold due to concentration risk, high valuation, and technical analysis indicating potential near-term downside. With a high P/E ratio of 60x, SMH is considered a poor capital allocation choice currently. Geopolitical risks, such as potential tariffs and tighter controls on semiconductor exports, could negatively impact its holdings and profitability.

Portfolio Pulse from

November 17, 2024 | 1:30 pm

LLY

Eli Lilly and Novo Nordisk are working to prevent compounded copies of their drugs, Ozempic and Zepbound, while facing challenges in scaling up production to meet demand.

Portfolio Pulse from

November 17, 2024 | 12:15 pm

EPIX

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. for potential violations of federal securities laws. This follows ESSA's announcement of ending its Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 17, 2024 | 1:00 am

OKLO

Investors are optimistic that the new Trump administration will boost the nuclear sector, potentially benefiting nuclear stocks.

Portfolio Pulse from

November 16, 2024 | 11:30 pm

BSX

Boston Scientific's WATCHMAN FLX™ device shows superior bleeding risk reduction compared to oral anticoagulants in the OPTION trial, while maintaining similar stroke risk reduction for atrial fibrillation patients post-cardiac ablation.

Portfolio Pulse from

November 16, 2024 | 8:30 pm

TMCI

The Schall Law Firm is investigating Treace Medical Concepts, Inc. for potential securities law violations, focusing on possible false or misleading statements made by the company.

Portfolio Pulse from

November 16, 2024 | 6:15 pm